

## Synthesis and characterization and biological evaluation of bivalent metal complexes with (E)-4-bromo-N'-(4-chlorobenzylidene) benzohydrazide ligand

Khalid Tuama Abdullah<sup>1</sup>, Alaa Mohammed Etheb<sup>2</sup>, Wedad Hameed Majeed<sup>3</sup>, Ahmed S.M. Al-Janabi<sup>1\*</sup>, Nasry Jassim Hussien<sup>5</sup>

<sup>1</sup>Department of Chemistry, College of Education for Pure Science, University of Diyala, Diyala, Iraq.

<sup>2</sup>Department of Biology, College of Science, University of Baghdad, Iraq.

<sup>3</sup>Ministry of Education/ First Karkh Education Directorate, Iraq.

<sup>4</sup>Department of Chemistry, College of Science, Tikrit University, Tikrit, Iraq; dr.ahmed.chem@tu.edu.iq (A.S.A.J.).

<sup>5</sup>Department of Chemistry, College of Education for Pure Science, University of Diyala, Iraq.

**Abstract:** New (E)-4-bromo-N'-(4-chlorobenzylidene)benzohydrazide (BrphOH) complexes of some bivalent metal ion complexes were synthesized and analyzed through microelemental investigation, infrared spectroscopy, conductivity measurements, and <sup>1</sup>H NMR spectroscopy. The BrphOH was bonded with the M(II) as a chelating ligand through the oxygen atom of the carbonyl group and the nitrogen atom of the azomethine group to afford octahedral complexes of the formula [MCl<sub>2</sub>(BrphOH)(H<sub>2</sub>O)<sub>2</sub>] {MII = Co (1), Ni (2), and Cu (3)}, or as a square planar complex of the type [PdCl<sub>2</sub>(BrphOH)](4), or as tetrahedral complexes of the formula [MCl<sub>2</sub>(BrphOH)] (MII = Zn (5), Cd (6), and Hg (7)). The prepared complexes were screened against Chlamydia trachomatis, Bacillus subtilis, Nosocomiicoccus ampullae, and Escherichia coli. The Palladium (II) and Nickel (II) complexes presented more advanced microbial action than the other compounds.

**Keywords:** Bacteria, Biological activity, Complexes, Isonicotinohydrazide, Schiff base.

### 1. Introduction

Hydrazide are a class of organic compounds formed by the condensation of hydrazide with aldehydes or ketones. They contain the functional group -C=N-NH-CO-. Hydrazide complexes are formed when these hydrazide molecules act as ligands and coordinate with metal ions. These complexes are of significant interest refer to their varied range of in medicine chemistry applicants, catalysis, and materials science [1-7]. The presence of a C=N (azomethine) group and carbonyl group allows hydrazide molecules to act as ligands and can act as mono, bidentate or poly-dentate ligands, coordinating to metal ions through nitrogen atom, oxygen atom or both. They often form stable chelate complexes with a variety transition metal ion (like copper, nickel, cobalt, and zinc), rare earth metals, and even lanthanides [2-17]. The formation of hydrazide-metal complexes can lead to various geometries, including square planar, octahedral, and tetrahedral arrangements, dependent on the ions and the environment of the hydrazide compound [1-7].

Hydrazide complexes have shown significant biological activities, including antibacterial, antifungal, anticancer, and antiviral properties. The coordination to metals can enhance the biological activity of the hydrazide ligand, making these complexes potential therapeutic agents [6, 8, 12]. Further the hydrazide complexes are used as catalysts in organic reactions, such as oxidation, reduction, and C-C coupling reactions, due to their ability to stabilize various oxidation states of the metal center [18, 19]. Also, these compounds can be used in the development of advanced materials, such as sensors, due to

their unique electronic and structural properties. According to the mentioned introduction, we didn't find any metal complexes synthesized from (E)-4-bromo-N'-(4-chlorobenzylidene) benzohydrazide. Consequently, this study focuses on synthesizing a variety of bivalent metal complexes with the hydrazone ligands and assessing how they function biologically against various pathogenic bacterial species.

## 2. Experiment Section

### 2.1. Apparatus

The NMR spectra were obtained at the King Saud University, Saudi, using a The ECZ Luminous™ (JNM-ECZL series) is an FT NMR spectrometer. Infrared spectra were obtained using a The JASCO FT/IR-6X FTIR spectrometer with KBr discs over the range of 400–4000  $\text{cm}^{-1}$ . Measurements of digital molar electric conductivity were obtained using the CD-2005 conductivity analyzer. Elemental investigations were conducted at the King Saud University, Saudi. Melting points were determined using a Hanon MP360 automatic slip melting point apparatus and were unadjusted. The (E)-4-bromo-N'-(4-chlorobenzylidene)benzohydrazide ligand was prepared according to the literature [20].

### 2.2. Preparation of $[\text{CoCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ (1)

A solution of the ligand (E)-4-bromo-N'-(4-chlorobenzylidene)benzohydrazide (BrphOH) (0.100g, 0.420mmol) in ethanol (10ml) was added to solution of  $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$  (0.141g, 0.420mmol) in distilled water (10ml) with stirring, the color was changed to an orange. The combination was stirred for 3 hours, throughout which an orange ppt. produced. The ppt. was filtered, washed with distilled water and ethanol, and dried under vacuum (Wt (g): 0.161 g; Yield 90%, m.p(°C): 261-262). The complexes  $[\text{NiCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$  (2),  $[\text{CuCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$  (3),  $[\text{PdCl}_2(\text{BrphOH})]$  (4),  $[\text{ZnCl}_2(\text{BrphOH})]$  (5),  $[\text{CdCl}_2(\text{BrphOH})]$  (6),  $[\text{HgCl}_2(\text{BrphOH})]$  (7), were synthesized by using similar method above.


### 2.3. Biological Activity

The standard agar diffusion method, initially detailed by Bauer, et al. [21] was employed to determine the activity index for all free hydrazone and its corresponding metal complexes. Tetracycline attended as the reference medication. The microbial activity was evaluated towards four pathogenic bacterial species. (*Chlamydia trachomatis*, *Bacillus subtilis*, *Nosocomiicoccus ampullae* and *Escherichia coli*.), at 0.001 M of newly DMSO of the prepared compounds. The results are listed in Table 4.

## 3. Results and Discussion

### 3.1. Preparation

Treatment of two moles of ((E)-4-bromo-N'-(4-chlorobenzylidene) benzohydrazide (BrphOH) with one equivalent mole of metal salt chlorides gave a complex of the type  $[\text{MCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$   $\{\text{M}^{\text{II}} = \text{Co}$  (1), Ni (2) and Cu (3)}, or complex of the type  $[\text{PdCl}_2(\text{BrphOH})]$  (4) or complexes of the type  $[\text{MCl}_2(\text{BrphOH})]$   $\{\text{M}^{\text{II}} = \text{Zn}$  (5), Cd (6) and Hg (7)} as a lone produce in good yield (71 - 94%) (Scheme 1).



**Figure 1.**  
Preparation pathway of the complexes (1-7).

The synthetic compounds exhibit stability and are soluble in dimethyl sulfoxide, and *N,N*-Dimethylformamide. The structures were subsequently analyzed by FT-IR, NMR, UV-Vis spectroscopy, molar conductivity, and magnetic susceptibility.

The ies measurements of the compounds in dimethyl sulfoxide solution ( $10^{-3}$  M at  $25^\circ\text{C}$ ) are considerably low, indicating that prepared complexes are not electrolyte solution [22]. The CHN analysis and a few physical characteristics are enumerated in Table 1.

**Table 1.**


Physical properties, product percentage, conductivity and CHN analysis for the prepared compounds.

| CHN analysis  |       |        | Produce % | m.p(C°) | Conductivity<br>(ohm <sup>-1</sup> . cm <sup>2</sup> . mol <sup>-1</sup> ) | Color           | Compounds  | Seq. |
|---------------|-------|--------|-----------|---------|--|-----------------|--|------|
| Found (cal.)% |       |        |           |         |  |                 |  |      |
| N             | H     | C      |           |         |  |                 |  |      |
| 8.52          | 3.13  | 49.93  | 93        | 151-152 | -  | Off white       | BrphOH   |      |
| -8.3          | -2.99 | -49.81 |           |         |  |                 |  |      |
| 5.72          | 2.75  | 33.42  | 90        | 261-263 | 9  | Yellowish green | [CoCl <sub>2</sub> (BrphOH)(H <sub>2</sub> O) <sub>2</sub> ] | 1.   |
| -5.56         | -2.8  | -33.4  |           |         |  |                 |  |      |
| 5.69          | 2.93  | 33.59  | 78        | 206-208 | 4.7  | Light green     | [NiCl <sub>2</sub> (BrphOH)(H <sub>2</sub> O) <sub>2</sub> ] | 2.   |
| -5.57         | -2.8  | -33.42 |           |         |  |                 |  |      |
| 5.73          | 2.91  | 33.29  | 83        | 198-201 | 11.5   | Blue            | [CuCl <sub>2</sub> (BrphOH)(H <sub>2</sub> O) <sub>2</sub> ] | 3.   |
| -5.51         | -2.78 | -33.1  |           |         |  |                 |  |      |
| 5.6           | 2.09  | 32.69  | 94        | 231-232 | 3.9  | Brown           | [PdCl <sub>2</sub> (BrphOH)]                                 | 4.   |
| -5.44         | -1.96 | -32.66 |           |         |  |                 |  |      |
| 6.17          | 2.24  | 35.69  | 71        | 249-252 | 1.4  | Off white       | [ZnCl <sub>2</sub> (BrphOH)]                                 | 5.   |
| -5.91         | -2.13 | -35.48 |           |         |  |                 |  |      |
| 5.62          | 2.14  | 32.33  | 79        | 269-271 | 10.5   | White           | [CdCl <sub>2</sub> (BrphOH)]                                 | 6.   |
| -5.38         | -1.94 | -32.28 |           |         |  |                 |  |      |
| 5.37          | 2.22  | 31.89  | 87        | 216-217 | 5.7  | White           | [HgCl <sub>2</sub> BrphOH](                                  | 7.   |
| -4.6          | -1.65 | -27.61 |           |         |  |                 |  |      |

### 3.2. Spectroscopic Studies


#### 3.2.1. <sup>1</sup>H NMR Spectra

The <sup>1</sup>H-NMR spectrum of free BrphOH (Figure 2) showed two singlet peak, the first appeared at  $\delta$ H= 8.92ppm which was attributed to the proton of the CH=N group and the second peak showed at the  $\delta$ H= 12.85ppm due to the (NH) group, the integration of these peaks represents one proton for each. Also, the spectrum displayed four doublet peaks at  $\delta$ H= 8.92 ppm (2H),  $\delta$ H= 8.58 ppm (2H),  $\delta$ H= 7.71 ppm (2H), and  $\delta$ H= 7.35 ppm (2H), refer to the protons in position 3, 2, 4 and 1, respectively, with the coupling constant is <sup>3</sup>J<sub>H-H</sub>= 8.00Hz. Each of these peaks agrees to two protons.



**Figure 2.**  
<sup>1</sup>H NMR spectrum of BrphOH ligand.

The  $^1\text{H}$ -NMR spectrum of free BrphOH (Figure 2) showed two singlet peak, the first appeared at  $\delta\text{H}= 8.92\text{ppm}$  and  $12.84\text{ ppm}$  due to the protons of  $\text{CH}=\text{N}$  and  $\text{NH}$ , respectively. In addition, the spectrum displayed four doublet peaks at  $\delta\text{H}= 8.76\text{ ppm}$  (2H),  $\delta\text{H}= 8.34\text{ ppm}$  (2H),  $\delta\text{H}= 7.54\text{ ppm}$  (2H), and  $\delta\text{H}= 7.45\text{ ppm}$  (2H), due to the protons in position 3, 2, 4 and 1, respectively. Each of these signals corresponds to two protons, as indicated by the integration values beneath each peak.



**Figure 3.**  
 $^1\text{H}$  NMR spectrum of  $[\text{PdCl}_2(\text{BrphOH})]$  complex.

In similar, the  $^1\text{H}$  NMR spectrum of  $[\text{MCl}_2(\text{BrphOH})]$  {  $\text{M}^{\text{II}} = \text{Zn}, \text{Cd}$  and  $\text{Hg}$  } complexes displayed the protons of the of the azomethine and  $\text{NH}$  groups as a singlet peaks with ( $\delta\text{H}= 8.61 - 8.70\text{ppm}$ ) and ( $\delta\text{H}= 12.81 - 12.93\text{ppm}$ ), each of these peaks agree to one proton as indicating from the integration values under each peak. Whereas the protons of the phenyl rings displayed in the aromatic region. All NMR results are listed in the Table 2.

**Table 2.**

$^1\text{H}$  NMR chemical shifts for the prepared complexes (in ppm).


| Complexes                        | $\delta\text{H}$ (ppm)   |
|----------------------------------|--|
| BrphOH                           | 12.85(s,1H, NH), 8.92 (s,1H, CH=N), 8.58 (d, 2H, H3), 8.35 (d, 2H, H2), 7.71 (d, 2H, H7), 7.25 (d, 2H, H8) |
| $[\text{PdCl}_2(\text{BrphOH})]$ | 12.84(s,1H, NH), 8.76 (d, 2H, H3), 8.57 (s,1H, CH=N), 8.34 (d, 2H, H2), 7.54 (d, 2H, H7), 7.45 (d, 2H, H8) |
| $[\text{ZnCl}_2(\text{BrphOH})]$ | 12.93(s,1H, NH), 8.81 (d, 2H, H3), 8.61 (s,1H, CH=N), 8.62 (d, 2H, H2), 7.76 (d, 2H, H7), 7.34 (d, 2H, H8) |
| $[\text{CdCl}_2(\text{BrphOH})]$ | 12.81(s,1H, NH), 8.79 (d, 2H, H3), 8.70 (s,1H, CH=N), 8.59 (d, 2H, H2), 7.83 (d, 2H, H7), 7.43 (d, 2H, H8) |
| $[\text{HgCl}_2(\text{BrphOH})]$ | 12.84(s,1H, NH), 8.83 (d, 2H, H3), 8.68 (s,1H, CH=N), 8.53 (d, 2H, H2), 7.70 (d, 2H, H7), 7.29 (d, 2H, H8) |

### 3.2.2. Infrared Spectra


The IR spectrum of the free (*E*)-4-bromo-*N*'-(4-chlorobenzylidene) benzohydrazide (BrphOH) ligand showed a four characteristic bands at 3176 $\text{cm}^{-1}$ , 1668  $\text{cm}^{-1}$ , 1593 $\text{cm}^{-1}$ , 1085 $\text{cm}^{-1}$  and 688 $\text{cm}^{-1}$  due to the  $\nu\text{N-H}$ ,  $\nu\text{C=O}$ ,  $\nu\text{C=N}$ ,  $\nu\text{N-N}$ , and  $\rho\text{C-H}$ , respectively, some of these bands were change after complexation with the metal ions (**Figure 5** and **5**). The vibration stretching frequency of the carbonyl group  $\nu(\text{C=O})$  and azomethine group  $\nu(\text{C=N})$  were displayed as a strong bands within (1634–1670)  $\text{cm}^{-1}$  and (1548–1562) $\text{cm}^{-1}$  range, respectively, the shifted towards lower frequencies than it was in the BrphOH ligand (showed at 1698  $\text{cm}^{-1}$  and 1593  $\text{cm}^{-1}$ ), designates that the BrphOH bonded as bidentate via the oxygen and nitrogen atoms of the  $\nu(\text{C=O})$  and  $\nu(\text{C=N})$  groups [23–25]. The spectra of the  $[\text{MCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$   $\{\text{M}^{\text{II}} = \text{Co}$  (**1**),  $\text{Ni}$  (**2**) and  $\text{Cu}$  (**3**) $\}$  displayed the coordinate hydrate vibration frequency at (923–923) $\text{cm}^{-1}$ , for the three complexes [26, 27]. Also, the spectra showed additional bands that were not present in spectrum of the free ligand, which are  $\nu(\text{M-O})$  and  $(\text{M-N})\nu$  which appeared at (467–490)  $\text{cm}^{-1}$  and (423–453)  $\text{cm}^{-1}$  respectively [24–29]. Additional bands are listed in Table 3.

**Table 3.**  
Selected IR bands of the prepared complexes (in  $\text{cm}^{-1}$ ).


| Compounds  | $\nu\text{N-H}$ | $\nu\text{C-H}$ |        | $\nu\text{C=O}$ | $\nu\text{C=N}$ | $\nu\text{C=C}$ | $\nu\text{N-N}$ | $\rho\text{C-H}$ | $\nu\text{M-O}$ | $\nu\text{M-N}$ |
|--|-----------------|-----------------|--------|-----------------|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|
|  |                 | Arom.           | Aliph. |                 |                 |                 |                 |                  |                 |                 |
| BrphOH   | 3174m           | 3028w           | 2848w  | 1698vs          | 1593m           | 1552m           | 1085m           | 754s             | -               | -               |
| $[\text{CoCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 3198m           | 3032w           | 2850w  | 1670vs          | 1558m           | 1546s           | 1078s           | 756s             | 467w            | 429w            |
| $[\text{NiCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 3212m           | 3014w           | 2898w  | 1655vs          | 1558s           | 1456m           | 1079s           | 752s             | 489w            | 437w            |
| $[\text{CuCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 3169w           | 3070w           | 2962w  | 1634vs          | 1569s           | 1550m           | 1087m           | 754s             | 484w            | 453w            |
| $[\text{PdCl}_2(\text{BrphOH})_2]$                     | 3171m           | 3068m           | 2966m  | 1648vs          | 1565s           | 1548s           | 1087s           | 752s             | 478w            | 453m            |
| $[\text{ZnCl}_2(\text{BrphOH})_2]$                     | 3209m           | 3056w           | 2923w  | 1652vs          | 1560s           | 1534s           | 1080s           | 745s             | 490w            | 438m            |
| $[\text{CdCl}_2(\text{BrphOH})_2]$                     | 3189s           | 3038w           | 2876w  | 1644vs          | 1548s           | 1542m           | 1084s           | 762s             | 467w            | 423m            |
| $[\text{HgCl}_2(\text{BrphOH})_2]$                     | 3166s           | 3062w           | 2989w  | 1656vs          | 1562s           | 1551s           | 1092s           | 748s             | 489w            | 441m            |



**Figure 4.**  
IR spectrum of free ligand.



**Figure 5.**  
IR spectrum of  $[\text{CuCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$  complex.



**Figure 6.**  
IR spectrum of  $[\text{PdCl}_2(\text{BrphOH})]$  complex.

### 3.2.3. Magnetic Moments and Electronic Data

The electronic data of the  $[\text{MCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$   $\{\text{M}^{\text{II}} = \text{Co (1), Ni (2) and Cu (3)}\}$  complexes displayed the characteristic bands for these complexes in the Uv-visible spectra which are listed in Table 4.

**Table 4.**

Electronic data and magnetic moments of the  $[\text{MCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$  complexes.

| Complexes  | Bands                   | Transitions   | State        | Magnetic moment | Geometry   |
|--|-------------------------|---|--------------|-----------------|------------|
| $[\text{CoCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 445 nm 734nm<br>1087nm  | ${}^4\text{T}_{1g} \rightarrow {}^4\text{T}_{1g}(\text{P})$<br>${}^4\text{T}_{1g} \rightarrow {}^4\text{A}_{2g}$<br>${}^4\text{T}_{1g} \rightarrow {}^4\text{T}_{2g}$   | Paramagnetic | 4.78 B.M        | Octahedral |
| $[\text{NiCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 389nm<br>578nm<br>813nm | ${}^3\text{A}_{2g}(\text{F}) \rightarrow {}^3\text{T}_{2g}(\text{F})$<br>${}^3\text{A}_{2g}(\text{F}) \rightarrow {}^3\text{T}_{1g}(\text{F})$<br>${}^3\text{A}_{2g}(\text{F}) \rightarrow {}^3\text{T}_{1g}(\text{P})$ | Paramagnetic | 2.98 B.M        | Octahedral |
| $[\text{CuCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 515nm 620nm             | d-d<br>${}^2\text{B}_{1g} \rightarrow {}^2\text{A}_{1g}$  | Paramagnetic | 2.04 B.M        | Octahedral |

The electronic spectra of the M(II) complexes exhibited bands absorption corresponding the octahedral geometry around the metal ions [30-33]. These results supporting by the magnetic moments of the metal ions.

### 3.3. Antibacterial Studies

The studies on the antibacterial activity of the free ligand and its synthesized complexes are presented in Table 5. The outcomes were obtained against four bacterial species: *Chlamydia trachomatis*, *Bacillus subtilis*, *Nosocomiicoccus ampullae*, and *Escherichia coli*. Figure 7 shows a summary of the results from the standard agar diffusion [21]. The size of the inhibitor region was contrasted to that of Tetracycline as a positive control. The comparative activity index (AI) percentage was computed as demonstrated below:

$$\% \text{ activity index} = \frac{\text{Inhibition zone of the test compounds}}{\text{Inhibition zone of the standard drug}} * 100.$$


**Table 5.**

DIZ (mm) and AI (%) of prepared complexes against pathogenic bacteria.

| Compounds  | Diameter Inhibition zone (mm) and AI (%) |     |         |     |                       |     |             |     |
|--|--|-----|---------|-----|-----------------------|-----|-------------|-----|
|  | Nosocomiicoccus ampullae                 |     | E. coli |     | Chlamydia trachomatis |     | B. subtilis |     |
| BrphOH   | 9  | 33  | 7       | 27  | 10                    | 40  | 11          | 42  |
| $[\text{CoCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 14                                       | 52  | 11      | 42  | 13                    | 52  | 14          | 54  |
| $[\text{NiCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 18                                       | 67  | 17      | 65  | 18                    | 72  | 20          | 77  |
| $[\text{CuCl}_2(\text{BrphOH})(\text{H}_2\text{O})_2]$ | 13                                       | 48  | 12      | 46  | 16                    | 64  | 18          | 69  |
| $[\text{PdCl}_2(\text{BrphOH})]$                       | 21                                       | 78  | 18      | 69  | 22                    | 88  | 23          | 88  |
| $[\text{ZnCl}_2(\text{BrphOH})]$                       | 13                                       | 48  | 14      | 54  | 11                    | 44  | 15          | 58  |
| <b>Tetracycline</b>                                    | 27                                       | 100 | 26      | 100 | 25                    | 100 | 26          | 100 |

All compounds exhibited insignificant activity compared to Tetracycline, yet surpassed that of the BrphOH ligand. The  $\text{Pd}^{+2}$  and  $\text{Ni}^{+2}$  complexes exhibited superior activity relative to further compounds. is 21mm, 18mm, 22mm and 23 mm against *Chlamydia trachomatis*, *Bacillus subtilis*, *Nosocomiicoccus ampullae*, and *Escherichia coli*, respectively. Whereas the Co-complex has lowest activity with DIZ is 14mm, 11mm, 13mm and 14mm against *Chlamydia trachomatis*, *Bacillus subtilis*, *Nosocomiicoccus ampullae*, and *Escherichia coli*, respectively.

Two theories elucidate the heightened activity of complexes: (1) the overtone concept, which posits that the solubility of compounds in the cell membrane significantly influences antibacterial activity by permitting the translocation of only lipid-soluble materials, and (2) [34] chelation theory, which asserts that the polarity of a metal ion is markedly diminished due to ligand orbital overlap and the distribution of positive charge among the central metallic ion and the ligand's donor atoms [34, 35].



**Figure 7.** histogram representation of free ligand and their complexes activity.

#### 4. Conclusion

The  $[MCl_2(BrphOH)(H_2O)_2]$   $\{M^{II} = Co$  (1), Ni (2) and Cu (3)  $\}$ ;  $[PdCl_2(BrphOH)]$ (4) and  $[MCl_2(BrphOH)]$   $\{M^{II} = Zn$  (5), Cd (6) and Hg (7)  $\}$  complexes were prepared and characterized by different physical and spectroscopic methods. The BrphOH ligand displayed a bidentate chelating ligand mode with the M(II) ion through oxygen and nitrogen atoms of carbonyl and azomethine groups respectively, to afford an octahedral geometry around the  $Co^{+2}$ ,  $Ni^{+2}$  and  $Cu^{+2}$  ions or square planer around  $Pd^{+2}$  ion, and whereas gave a tetrahedral with the  $Zn^{+2}$ ,  $Cd^{+2}$  and  $Hg^{+2}$  ions. Finally, the biological activity has been screened against four pathogenic. The  $Pd^{+2}$  and  $Ni^{+2}$  complexes exhibited superior activity relative to further compounds. is 21mm, 18mm, 22mm and 23 mm against *Chlamydia trachomatis*, *Bacillus subtilis*, *Nosocomiicoccus ampullae*, and *Escherichia coli*, respectively.

#### Transparency:

The authors confirm that the manuscript is an honest, accurate, and transparent account of the study; that no vital features of the study have been omitted; and that any discrepancies from the study as planned have been explained. This study followed all ethical practices during writing.

#### Copyright:

© 2025 by the authors. This open-access article is distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

#### References

- [1] R. Narang, B. Narasimhan, and S. Sharma, "A review on biological activities and chemical synthesis of hydrazide derivatives," *Current Medicinal Chemistry*, vol. 19, no. 4, pp. 569-612, 2012. <https://doi.org/10.2174/092986712798918789>

- [2] M. S. Khan, S. P. Siddiqui, and N. Tarannum, "A systematic review on the synthesis and biological activity of hydrazide derivatives," *Hygeia. Journal for Drugs and Medicines*, vol. 9, pp. 61-79, 2017. <https://doi.org/10.15254/H.J.D.Med.9.2017.165>
- [3] J. Dilworth, "Diazene, diazenido, isodiazene and hydrazido complexes," *Coordination Chemistry Reviews*, vol. 330, pp. 53-94, 2017. <https://doi.org/10.1016/j.ccr.2016.09.006>
- [4] M. M. Shakdofa, M. H. Shtaiwi, N. Morsy, and T. M. Abdel-rassel, "Metal complexes of hydrazones and their biological, analytical and catalytic applications: A review," *Main Group Chemistry*, vol. 13, no. 3, pp. 187-218, 2014. <https://doi.org/10.3233/MGC-140133>
- [5] N. Ribeiro and I. Correia, "A review of hydrazide-hydrazone metal complexes' antitumor potential," *Frontiers in Chemical Biology*, vol. 3, p. 1398873, 2024. <https://doi.org/10.3389/fchbi.2024.1398873>
- [6] S. Murugappan, S. Dastari, K. Jungare, N. M. Barve, and N. Shankaraiah, "Hydrazide-hydrazone/hydrazone as enabling linkers in anti-cancer drug discovery: A comprehensive review," *Journal of Molecular Structure*, p. 138012, 2024. <https://doi.org/10.1016/j.molstruc.2024.138012>
- [7] S. N. Mali, B. R. Thorat, D. R. Gupta, and A. Pandey, "Mini-review of the importance of hydrazides and their derivatives—Synthesis and biological activity," *Engineering Proceedings*, vol. 11, no. 1, p. 21, 2021. <https://doi.org/10.3390/ASEC2021-11157>
- [8] A. Kriza, V. L. Ababei, N. Cioatera, I. Rău, and N. Stănică, "Synthesis and structural studies of complexes of Cu, Co, Ni and Zn with isonicotinic acid hydrazide and isonicotinic acid (1-naphthylmethylene) hydrazide," *Journal of the Serbian Chemical Society*, vol. 75, no. 2, pp. 229-242, 2010. <https://doi.org/10.2298/JSC1002229K>
- [9] S. Parveen *et al.*, "Design, synthesis and spectroscopic characterizations of medicinal hydrazide derivatives and metal complexes of malonic ester," *Current Bioactive Compounds*, vol. 19, no. 4, pp. 31-46, 2023. <https://doi.org/10.2174/1573407218666211222124947>
- [10] H. Louis *et al.*, "Retracted Article: Computational design and molecular modeling of the interaction of nicotinic acid hydrazide nickel-based complexes with H<sub>2</sub>S gas," *RSC Advances*, vol. 12, no. 47, pp. 30365-30380, 2022.
- [11] D. A. Tolan, T. I. Kashar, K. Yoshizawa, and A. M. El-Nahas, "Synthesis, spectral characterization, density functional theory studies, and biological screening of some transition metal complexes of a novel hydrazide-hydrazone ligand of isonicotinic acid," *Applied Organometallic Chemistry*, vol. 35, no. 6, p. e6205, 2021. <https://doi.org/10.1002/aoc.6205>
- [12] T. A. Yousef, L. H. Al-Jibori, A. S. Fiahan, A. O. Elzupir, M. M. Abou-Krishna, and A. S. Al-Janabi, "Benzohydrazide derivative metal complex's antimicrobial and inhibitory effects on liver cancer cell lines and quinone oxidoreductase 2: Experimental, molecular docking, and DFT investigations," *Journal of Molecular Structure*, vol. 1308, p. 138073, 2024. <https://doi.org/10.1016/j.molstruc.2024.138073>
- [13] L. H. Al-Jibori and A. S. Marmus, "Synthesis, spectroscopic analysis, and anti-bacterial studies of Pd (II) complexes of phosphine and hydrazone derivatives," *Journal of the Turkish Chemical Society Section A: Chemistry*, vol. 11, no. 1, pp. 245-252, 2024.
- [14] S. K. Tadavi, R. S. Bendre, S. V. Patil, S. Gaguna, and J. D. Rajput, "Synthesis, crystal structures and antimicrobial activity of palladium metal complexes of sulfonyl hydrazone ligands," *European Journal of Chemistry*, vol. 11, no. 4, pp. 377-384, 2020. <https://doi.org/10.5155/eurjchem.11.4.377-384.2040>
- [15] M. M. Đorđević, D. A. Jeremić, M. V. Rodić, V. S. Simić, I. D. Brčeski, and V. M. Leovac, "Synthesis, structure and biological activities of Pd (II) and Pt (II) complexes with 2-(diphenylphosphino) benzaldehyde 1-adamantonylhydrazone," *Polyhedron*, vol. 68, pp. 234-240, 2014. <https://doi.org/10.1016/j.poly.2013.10.029>
- [16] L. Abdel-Rahman *et al.*, "Chemical, physical, and biological properties of Pd (II), V (IV) O, and Ag (I) complexes of N3 tridentate pyridine-based Schiff base ligand," *Journal of Coordination Chemistry*, vol. 73, no. 23, pp. 3150-3173, 2020.
- [17] H.-Q. Chang *et al.*, "Syntheses, crystal structures, antitumor and antioxidant activities of two hydrazide-hydrazone-based transition metal complexes," *Transition Metal Chemistry*, vol. 40, pp. 485-491, 2015. <https://doi.org/10.1007/s11243-015-9938-x>
- [18] A. Ashma *et al.*, "Synthesis of new nicotinic acid hydrazide metal complexes: Potential anti-cancer drug, supramolecular architecture, antibacterial studies and catalytic properties," *Journal of Molecular Structure*, vol. 1250, p. 131860, 2022.
- [19] M. Ghorbanloo, H. H. Monfared, and C. Janiak, "The catalytic function of a silica gel-immobilized Mn (II)-hydrazide complex for alkene epoxidation with H<sub>2</sub>O<sub>2</sub>," *Journal of Molecular Catalysis A: Chemical*, vol. 345, no. 1-2, pp. 12-20, 2011. <https://doi.org/10.1016/j.molcata.2011.05.014>
- [20] R. O. Khalid, A. S. Al-Janabi, A. A. Al-Bayati, and M. Alheety, "Bivalent metal complexes of N'-(4-chlorobenzylidene) isonicotinohydrazide: Synthesis, characterization, biological, DFT and hydrogen storage studies," *Journal of Molecular Structure*, vol. 1323, p. 140721, 2025. <https://doi.org/10.1016/j.molstruc.2024.140721>
- [21] A. W. Bauer, D. M. Perry, and W. M. Kirby, "Single-disk antibiotic-sensitivity testing of staphylococci: An analysis of technique and results," *AMA Archives of Internal Medicine*, vol. 104, no. 2, pp. 208-216, 1959. <https://doi.org/10.1001/archinte.1959.00270020034006>

- [22] W. J. Geary, "The use of conductivity measurements in organic solvents for the characterisation of coordination compounds," *Coordination Chemistry Reviews*, vol. 7, no. 1, pp. 81-122, 1971. [https://doi.org/10.1016/S0010-8545\(00\)80009-0](https://doi.org/10.1016/S0010-8545(00)80009-0)
- [23] A. S. Al-Janabi *et al.*, "Spectroscopic, anti-bacterial, anti-cancer and molecular docking of Pd (II) and Pt (II) complexes with (E)-4-((dimethylamino) methyl)-2-((4, 5-dimethylthiazol-2-yl) diazenyl) phenol ligand," *Journal of Saudi Chemical Society*, vol. 27, no. 3, p. 101619, 2023. <https://doi.org/10.1016/j.jscs.2023.101619>
- [24] M. M. Salih, A. M. Saleh, A. S. Hamad, and A. S. Al-Janabi, "Synthesis, spectroscopic, anti-bacterial activity, molecular docking, ADMET, toxicity and DNA binding studies of divalent metal complexes of pyrazole-3-one azo ligand," *Journal of Molecular Structure*, vol. 1264, p. 133252, 2022. <https://doi.org/10.1016/j.molstruc.2022.133252>
- [25] A. S. Al-Janabi, R. Zaky, T. A. Yousef, B. S. Nomi, and S. Shaaban, "Synthesis, characterization, computational simulation, biological and anticancer evaluation of Pd (II), Pt (II), Zn (II), Cd (II), and Hg (II) complexes with 2-amino-4-phenyl-5-selenocyanatothiazol ligand," *Journal of the Chinese Chemical Society*, vol. 67, no. 6, pp. 1032-1044, 2020. <https://doi.org/10.1002/jccs.201900454>
- [26] A. S. Al-Janabi, A. F. Al-Bayati, O. A. ALtaie, A. O. Elzupir, and T. A. Yousef, "Co (II), Ni (II), and Zn (II) complexes of 5-methyl-1, 3, 4-oxadiazol-2-amine Schiff base as potential heat shock protein 90 inhibitors: Spectroscopic, biological activity, density functional theory, and molecular docking studies," *Applied Organometallic Chemistry*, vol. 36, no. 12, p. e6899, 2022. <https://doi.org/10.1002/aoc.6899>
- [27] A. S. Al-Janabi, A. O. Elzupir, M. M. Abou-Krishna, and T. A. Yousef, "New dual inhibitors of SARS-CoV-2 based on metal complexes with Schiff-base 4-chloro-3-methyl phenyl hydrazine: Synthesis, DFT, antibacterial properties and molecular docking studies," *Inorganics*, vol. 11, no. 2, p. 63, 2023. <https://doi.org/10.3390/inorganics11020063>
- [28] A. M. Al-Janabi, A. S. Faihan, A. M. Al-Mutairi, M. R. Hatshan, S. A. Al-Jibori, and A. S. Al-Janabi, "Spectroscopic, biological activity studies, and DFT calculations, of Pd (II) and Pt (II) complexes of 4-Methylene-3-phenyl-3, 4-dihydroquinazoline-2 (1H)-thione," *Journal of the Indian Chemical Society*, vol. 99, no. 11, p. 100774, 2022.
- [29] A. Osama'a, O. R. Al Samarrai, T. A. Yousef, M. M. Abou-Krishna, M. H. Alhalafi, and A. S. Al-Janabi, "Synthesis, spectroscopic, DFT, anticancer evaluation and enzyme inhibition studies of platinum (II) complexes with 1-methyl-1H-1, 2, 3, 4-tetrazole-5-thiol and phosphine ligands: Crystal structure of [Pt (mtzt) 2 (dppe)]," *Chemical Physics Impact*, vol. 8, p. 100581, 2024. <https://doi.org/10.1016/j.cphi.2024.100581>
- [30] D. Nicholls and D. Nicholls, "Electronic spectra of transition-metal complexes," *Complexes and First-Row Transition Elements*, pp. 73-99, 1974.
- [31] G. A. Crosby, "Spectroscopic investigations of excited states of transition-metal complexes," *Accounts of Chemical Research*, vol. 8, no. 7, pp. 231-238, 1975. <https://doi.org/10.1021/ar50076a003>
- [32] P. Jyothi, S. Koppu, V. Sumalatha, B. Ushaiah, and C. G. Kumari, "Synthesis, characterisation, cytotoxicity, DNA binding and antimicrobial studies of binary and ternary metal complexes of Co (II)," *Inorganic Chemistry Communications*, vol. 110, p. 107590, 2019. <https://doi.org/10.1016/j.inoche.2019.107590>
- [33] S. AbouEl-Enein, F. A. El-Saied, S. M. Emam, and M. Ell-Salamony, "First row transition metal complexes of salicylidene and 2-hydroxy-1-naphthylidene-N-cyanoacetohydrazone," *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, vol. 71, no. 2, pp. 421-429, 2008. <https://doi.org/10.1016/j.saa.2008.03.043>
- [34] B. Tweedy, "Plant extracts with metal ions as potential antimicrobial agents," *Phytopathology*, vol. 55, no. 8, pp. 910-914, 1964. <https://doi.org/10.1094/Phyto-55-910>
- [35] K. T. Abdullah *et al.*, "Spectroscopic and biological studies of Pd (II) complexes of 5-(p-tolyl)-1, 3, 4-oxadiazole-2-thiol," *Bulletin of the Chemical Society of Ethiopia*, vol. 39, no. 1, pp. 79-90, 2025. <https://doi.org/10.4314/bcse.v39i1.6>